Cargando…

Long-Term Outcomes of the 150 mm Drug-Coated Balloon Cohort from the IN.PACT Global Study

PURPOSE: Data on the long-term safety and effectiveness of drug-coated balloons (DCBs) for the treatment of long femoropopliteal atherosclerotic lesions in the real-world setting are rare. This study reports 3 year and 5 year outcomes of the pre-specified 150 mm balloon sub-cohort of the IN.PACT Glo...

Descripción completa

Detalles Bibliográficos
Autores principales: Brodmann, Marianne, Lansink, Wouter, Guetl, Katharina, Micari, Antonio, Menk, Jeremiah, Zeller, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458561/
https://www.ncbi.nlm.nih.gov/pubmed/35864209
http://dx.doi.org/10.1007/s00270-022-03214-y
_version_ 1784786318900854784
author Brodmann, Marianne
Lansink, Wouter
Guetl, Katharina
Micari, Antonio
Menk, Jeremiah
Zeller, Thomas
author_facet Brodmann, Marianne
Lansink, Wouter
Guetl, Katharina
Micari, Antonio
Menk, Jeremiah
Zeller, Thomas
author_sort Brodmann, Marianne
collection PubMed
description PURPOSE: Data on the long-term safety and effectiveness of drug-coated balloons (DCBs) for the treatment of long femoropopliteal atherosclerotic lesions in the real-world setting are rare. This study reports 3 year and 5 year outcomes of the pre-specified 150 mm balloon sub-cohort of the IN.PACT Global Study. METHODS: The IN.PACT Global Study was a prospective, multicentre, international, single-arm study evaluating the performance of the IN.PACT Admiral DCB in real-world patients with femoropopliteal atherosclerotic disease. This pre-specified 150 mm DCB cohort analysis comprised 107 participants (111 lesions) with all target lesions treated with at least one 150 mm DCB. RESULTS: Mean lesion length was 20.3 ± 9.2 cm; 18.0% had in-stent restenosis, 58.6% were totally occluded, and 17.1% were severely calcified. Through 60 months, the Kaplan–Meier estimate of freedom from clinically driven target lesion revascularization (CD-TLR) was 72.7% [95% confidence interval (CI):62.4%–80.5%]. The safety composite endpoint (freedom from device/procedure-related death through 30 days; freedom from target limb major amputation and clinically driven target vessel revascularization through 5 years) was 70.5%. The cumulative incidence of major amputation was 1.0% and all-cause mortality was 18.4% through 60 months. Freedom from CD-TLR rates in the provisional stented and non-stented subgroups through 36 months were 64.0% [95% CI: 46.1%–77.3%] and 81.9% [95% CI: 69.7%–89.6%] (log-rank p = 0.074), respectively. CONCLUSIONS: The results demonstrate sustained long-term safety of the 150 mm IN.PACT Admiral DCB for long femoropopliteal atherosclerotic lesions in real-world patients. In particular, the results show that DCB angioplasty is an effective revascularization modality in long complex lesions. ClinicalTrials.gov identifier: NCT01609296. LEVEL OF EVIDENCE. Level 3, Cohort Study. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00270-022-03214-y.
format Online
Article
Text
id pubmed-9458561
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-94585612022-09-10 Long-Term Outcomes of the 150 mm Drug-Coated Balloon Cohort from the IN.PACT Global Study Brodmann, Marianne Lansink, Wouter Guetl, Katharina Micari, Antonio Menk, Jeremiah Zeller, Thomas Cardiovasc Intervent Radiol Clinical Investigation PURPOSE: Data on the long-term safety and effectiveness of drug-coated balloons (DCBs) for the treatment of long femoropopliteal atherosclerotic lesions in the real-world setting are rare. This study reports 3 year and 5 year outcomes of the pre-specified 150 mm balloon sub-cohort of the IN.PACT Global Study. METHODS: The IN.PACT Global Study was a prospective, multicentre, international, single-arm study evaluating the performance of the IN.PACT Admiral DCB in real-world patients with femoropopliteal atherosclerotic disease. This pre-specified 150 mm DCB cohort analysis comprised 107 participants (111 lesions) with all target lesions treated with at least one 150 mm DCB. RESULTS: Mean lesion length was 20.3 ± 9.2 cm; 18.0% had in-stent restenosis, 58.6% were totally occluded, and 17.1% were severely calcified. Through 60 months, the Kaplan–Meier estimate of freedom from clinically driven target lesion revascularization (CD-TLR) was 72.7% [95% confidence interval (CI):62.4%–80.5%]. The safety composite endpoint (freedom from device/procedure-related death through 30 days; freedom from target limb major amputation and clinically driven target vessel revascularization through 5 years) was 70.5%. The cumulative incidence of major amputation was 1.0% and all-cause mortality was 18.4% through 60 months. Freedom from CD-TLR rates in the provisional stented and non-stented subgroups through 36 months were 64.0% [95% CI: 46.1%–77.3%] and 81.9% [95% CI: 69.7%–89.6%] (log-rank p = 0.074), respectively. CONCLUSIONS: The results demonstrate sustained long-term safety of the 150 mm IN.PACT Admiral DCB for long femoropopliteal atherosclerotic lesions in real-world patients. In particular, the results show that DCB angioplasty is an effective revascularization modality in long complex lesions. ClinicalTrials.gov identifier: NCT01609296. LEVEL OF EVIDENCE. Level 3, Cohort Study. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00270-022-03214-y. Springer US 2022-07-21 2022 /pmc/articles/PMC9458561/ /pubmed/35864209 http://dx.doi.org/10.1007/s00270-022-03214-y Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Clinical Investigation
Brodmann, Marianne
Lansink, Wouter
Guetl, Katharina
Micari, Antonio
Menk, Jeremiah
Zeller, Thomas
Long-Term Outcomes of the 150 mm Drug-Coated Balloon Cohort from the IN.PACT Global Study
title Long-Term Outcomes of the 150 mm Drug-Coated Balloon Cohort from the IN.PACT Global Study
title_full Long-Term Outcomes of the 150 mm Drug-Coated Balloon Cohort from the IN.PACT Global Study
title_fullStr Long-Term Outcomes of the 150 mm Drug-Coated Balloon Cohort from the IN.PACT Global Study
title_full_unstemmed Long-Term Outcomes of the 150 mm Drug-Coated Balloon Cohort from the IN.PACT Global Study
title_short Long-Term Outcomes of the 150 mm Drug-Coated Balloon Cohort from the IN.PACT Global Study
title_sort long-term outcomes of the 150 mm drug-coated balloon cohort from the in.pact global study
topic Clinical Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458561/
https://www.ncbi.nlm.nih.gov/pubmed/35864209
http://dx.doi.org/10.1007/s00270-022-03214-y
work_keys_str_mv AT brodmannmarianne longtermoutcomesofthe150mmdrugcoatedballooncohortfromtheinpactglobalstudy
AT lansinkwouter longtermoutcomesofthe150mmdrugcoatedballooncohortfromtheinpactglobalstudy
AT guetlkatharina longtermoutcomesofthe150mmdrugcoatedballooncohortfromtheinpactglobalstudy
AT micariantonio longtermoutcomesofthe150mmdrugcoatedballooncohortfromtheinpactglobalstudy
AT menkjeremiah longtermoutcomesofthe150mmdrugcoatedballooncohortfromtheinpactglobalstudy
AT zellerthomas longtermoutcomesofthe150mmdrugcoatedballooncohortfromtheinpactglobalstudy